TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26342472
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of dual antiplatelet therapy (DAPT)
Study: 24712378
Drug: 15 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g/d yellow pea fibre
Study: 20598833
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch (NP)
Study: 17569128
Drug: lamivudine, interferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: lamivudine, interferon alpha (IFN‐alpha 2b), or sequential therapy with lamivudine-IFN‐alpha 2b for 48 weeks
Study: 15305694
Drug: Highly Active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly Active AntiRetroviral Therapy (HAART)
Study: 9794107
Drug: Homozygous for
Normalized name: HOMOZYGOUS YUCATAN MINIATURE PIG ATAXIA TELANGIECTASIA MUTATED (ATM) GENE DISRUPTED BY A ATM-NEO RDNA CONSTRUCT IN EXON 57
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homozygous for the codon 354 variant (GIP receptor variant)
Study: 9794107
Drug: Wild-type receptor
Normalized name: Influenza A virus A/Brisbane/10/2010 (H1N1) wild type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wild-type receptor
Study: 7641350
Drug: Hirulog 0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirulog 0.02 mg.kg‐1.h‐1
Study: 7641350
Drug: Hirulog 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirulog 0.25 mg.kg‐1.h‐1
Study: 7641350
Drug: Hirulog 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirulog 0.5 mg.kg‐1.h‐1
Study: 7641350
Drug: Hirulog 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirulog 1.0 mg.kg‐1.h‐1
Study: 7641350
Drug: Hirulog (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirulog (all doses)
Study: 319815
Drug: Doxapram 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxapram 80 mg i.v.
Study: 25171883
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of triamcinolone at the borders of the wall lacerations during each dilation session
Study: 23305566
Drug: Weekly Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly Group - 30 mg elemental iron weekly for 10 months (40 doses)
Study: 23305566
Drug: Cyclical Group
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclical Group - 30 mg elemental iron daily for 20 days, two cycles separated by four months (40 doses total)
Study: 7720760
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg sublingual ISDN
Study: 7720760
Drug: 300-kcal, 300-ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300-kcal, 300-ml mixed liquid meal
Study: 7720760
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg sublingual ISDN followed by meal
Study: 7720760
Drug: meal followed
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: meal followed by 5 mg sublingual ISDN
Study: 2188182
Drug: Diet plus
Normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet plus insulin (20 units NPH and 10 units regular)
Study: 7434206
Drug: Cerium nitrate-silver
Normalized name: potassium nitrate / silver nitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerium nitrate-silver sulfadiazine cream
Study: 21880242
Drug: Pioglitazone (30/45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30/45 mg)
Study: 21880242
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Pioglitazone and Ramipril (PIRA)
Study: 21880242
Drug: Ramipril (2.5/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (2.5/5 mg)
Study: 55586
Drug: Three biscuits
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three biscuits daily each containing 10 g of ordinary miller's bran
Study: 16308544
Drug: Salbutamol (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (12 mg/day)
Study: 16308544
Drug: Salbutamol (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (12 mg/day) + Theophylline (200 mg/day)
Study: 11500251
Drug: Progesterone (25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (25, 50, 100 mg im)
Study: 11500251
Drug: Progesterone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (100 mg im)
Study: 8342904
Drug: Prednisolone, 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone, 0.6 mg/kg/day for 2 weeks
Study: 29246847
Drug: clinic‐based manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: clinic‐based manual therapy and individualized exercise
Study: 25050337
Drug: Bee venom
Normalized name: Bee venom
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bee venom (BV) ointment applied locally over masseter muscles for 14 days during a 3-minute massage.
Study: 25050337
Drug: Bee venom
Normalized name: Bee venom
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bee venom (BV) ointment
Study: 25050337
Drug: 0.0005% BV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0005% BV ointment
Study: 22023069
Drug: Zinc 250mg
Normalized name: zinc oxide 250 MG/ML
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc 250mg administered concurrently with cephalexin 500mg
Study: 22023069
Drug: Zinc 250mg
Normalized name: zinc oxide 250 MG/ML
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc 250mg administered 3h before cephalexin 500mg
Study: 22023069
Drug: Zinc 250mg
Normalized name: zinc oxide 250 MG/ML
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc 250mg administered 3h after cephalexin 500mg
Study: 19935771
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) plus weekly paclitaxel
Study: 18416586
Drug: pegylated interferon-alpha-2a
Normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pegylated interferon-alpha-2a 180 microg once weekly plus ribavirin 15 mg/kg/day
Study: 18416586
Drug: pegylated interferon-alpha-2b
Normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: pegylated interferon-alpha-2b 1.5 microg/kg once weekly plus ribavirin 15 mg/kg/day
Study: 15948518
Drug: 6% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% hydrogen peroxide tooth bleaching gel delivered on polyethylene film (HP)
Study: 15948518
Drug: 18% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18% carbamide peroxide brush-applied liquid gel (CP)
Study: 15948518
Drug: L*a*b* values
Approvals — FDA: no, EMA: no, PMDA: no
Description: L*a*b* values from ShadeVision System for HP
Study: 31015221
Drug: Usual care,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care, handwritten discharge prescription (control group)
Study: 23221418
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia cream (EMLA)
Study: 31016340
Drug: Reduced radiation
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced radiation dose (RD) with −20%, −40%, −57%, or −80% CT radiation dose combined with iterative model‐based reconstruction (IMR) levels 1–3
Study: 31016340
Drug: Full radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full radiation dose (FD) with iterative reconstruction (iDose4)
Study: 28464211
Drug: Oral osteoporosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral osteoporosis therapy (OPT)
Study: 28464211
Drug: No osteoporosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: No osteoporosis therapy (OPT)
Study: 25653079
Drug: Video-game based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video-game based therapy (VGT) using Xbox with Kinect device for 16 sessions
Study: 25653079
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (CT) for 16 sessions
Study: 25653079
Drug: Video-game based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video-game based therapy (VGT)
Study: 22122818
Drug: Benazepril (BENA)
DrugBank: Benazepril (DB00542)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benazepril (BENA) 20 mg with HCTZ 25 mg
Study: 22122818
Drug: Valsartan (VAL)
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan (VAL) 160 mg with HCTZ 12.5 mg
Study: 18466655
Drug: Gum arabic
Normalized name: Gum arabic
DrugBank: Acacia (DB10451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gum arabic (10 g daily)
Study: 18466655
Drug: Positive control
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive control (10 g inulin)
Study: 9345019
Drug: Hydroxyurea (HU)
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (HU) 25 mg/kg/d, followed by low-dose maintenance
Study: 9345019
Drug: Pipobroman (Pi)
Normalized name: pipobroman
DrugBank: Pipobroman (DB00236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pipobroman (Pi) 1.2 mg/kg/d, followed by low-dose maintenance
Study: 8445429
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine and asparaginase administered at 7-day intervals
Study: 8445429
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine and asparaginase with no maintenance therapy
Study: 8445429
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine and asparaginase intensification
Study: 3756365
Drug: Low-dose IV
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IV Metoclopramide (total dose: 0.8 mg/kg)
Study: 3756365
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Metoclopramide plus Nortriptyline (2 X 50 mg PO) plus Thiethylperazine (3 X 10 mg IV)
Study: 3756365
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Metoclopramide plus Nortriptyline plus Thiethylperazine
Study: 30388029
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of methylphenidate and behavior therapy
Study: 27079434
Drug: Topiroxostat 40-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiroxostat 40-120 mg/day
Study: 27079434
Drug: Topiroxostat 80-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiroxostat 80-120 mg/day
Study: 25172379
Drug: BRADA diet
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRADA diet (Brazilian Dietary Approach to Break Hypertension), orientation and planned monthly menus, duration 6 months
Study: 23759039
Drug: Metoclopramide 20
Normalized name: metoclopramide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 20 mg as a bolus
Study: 23759039
Drug: Metoclopramide 20
Normalized name: metoclopramide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 20 mg infused over 15 min
Study: 20726279
Drug: Eszopiclone (ESZ)
Normalized name: Eszopiclone
DrugBank: Eszopiclone (DB00402)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eszopiclone (ESZ) 3 mg
Study: 17653697
Drug: Gaboxadol 20
Normalized name: Gaboxadol
DrugBank: Gaboxadol (DB06554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaboxadol 20 mg (GBX20)
Study: 15515282
Drug: Educational tool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational tool for oral care guidelines
Study: 2466024
Drug: placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo therapy control group (normal saline)
Study: 31590108
Drug: Cryotherapy (cooling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy (cooling hands and feet with crushed ice during paclitaxel treatment)
Study: 27821917
Drug: Active rehabilitation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active rehabilitation therapy (two types of rehabilitation programs, four times per week for eight weeks)
Study: 27821917
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no active rehabilitation therapy)
Study: 27821917
Drug: Active rehabilitation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active rehabilitation therapy
Study: 24791863
Drug: Salmeterol xinafoate/fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol xinafoate/fluticasone propionate (SF; Seretide, GlaxoSmithKline) Diskus (50/500 µg twice daily)
Study: 24791863
Drug: Ipratropium bromide/salbutamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipratropium bromide/salbutamol (IS; Combivent, Boehringer Ingelheim) MDI (42 µg/240 µg quartic daily)
Study: 20157179
Drug: Periodic presumptive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodic presumptive treatment (PPT) followed by syndromic treatment and condom-use promotion
Study: 20157179
Drug: Periodic presumptive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodic presumptive treatment (PPT)
Study: 17222115
Drug: IvIg 2
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IvIg 2 g/kg body weight
Study: 15804151
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of APP, CS, and Aprotinin
Study: 12584830
Drug: Shenle capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenle capsule (SLC)
Study: 10613620
Drug: Tramadol 200
Normalized name: TRAMADOL 200MG (RYZOLT) SA TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 200 to 400 mg/day
Study: 7577277
Drug: Continuous thoracic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous thoracic extradural infusion of bupivacaine
Study: 1785269
Drug: Intracervical gel
Normalized name: eladocagene exuparvovec
DrugBank: Eladocagene exuparvovec (DB16780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical gel with 0.5 mg PGE2 (n = 116)
Study: 1785269
Drug: Vagitories containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vagitories containing 2.5 mg PGE2 (n = 110)
Study: 28314866
Drug: single ALA-PDT
Approvals — FDA: no, EMA: no, PMDA: no
Description: single ALA-PDT treatment
Study: 25468473
Drug: Human recombinant
Normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human recombinant growth hormone
Study: 23582009
Drug: Low-dose Epo
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Epo (63 IU/kg)
Study: 23582009
Drug: High-dose Epo
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Epo (400 IU/kg)
Study: 23582009
Drug: Putative mediators
Normalized name: Mcla-128 (igg1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (adcc) activity targeting her2 and her3 receptors.)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Putative mediators of hepcidin repression (transferrin saturation, soluble transferrin receptor, growth differentiation factor 15)
Study: 17728422
Drug: Mirtazapine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (30 mg/day) for 8 weeks, followed by citalopram if insufficient response
Study: 17728422
Drug: Nonresponders to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonresponders to antidepressant treatment
Study: 15499897
Drug: Intradermal (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) vaccination (4 microg)
Study: 15499897
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) vaccination (20 microg)
Study: 9820611
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous infusion of recombinant human erythropoietin (rhEPO) at a flow rate of 6000 IU per week (36 IU/h)
Study: 9820611
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous infusion of recombinant human erythropoietin (rhEPO)
Study: 9820611
Drug: Weekly bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly bolus subcutaneous injection of recombinant human erythropoietin (rhEPO) at a dose of 6000 IU
Study: 8584530
Drug: salbutamol 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: salbutamol 0.2 mg (test effect)
Study: 8584530
Drug: fenoterol 0.2
Normalized name: fenoterol 0.25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenoterol 0.2 mg, salbutamol 0.2 mg, salmeterol 0.05 mg (best effect)
Study: 8584530
Drug: beta 2‐agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta 2‐agonist (TGV reduction)
Study: 27602992
Drug: Structured and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured and therapist-guided internet intervention based on solution-focused and cognitive-behavioral therapy
Study: 23558871
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus heparin (Group 1, n = 60) - 80 mg daily aspirin orally and 5000 U unfractionated heparin per 8 h subcutaneously from admission to discharge.
Study: 23558871
Drug: Heparin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin alone (Group 2, n = 60) - same dose of heparin alone.
Study: 23558871
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus heparin (Group 1)
Study: 23558871
Drug: Heparin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin alone (Group 2)
Study: 16157399
Drug: Betaxolol 20
Normalized name: betaxolol 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol 20 mg od
Study: 11192711
Drug: E5510 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: E5510 (4 mg x day(-1))
Study: 11192711
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no anti-thrombotic medication)
Study: 1686581
Drug: Glutamic acid
Normalized name: Glutamic Acid
DrugBank: Glutamic acid (DB00142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamic acid hydrochloride (two 680-mg doses given 10 minutes apart)
Study: 1686581
Drug: Glutamic acid
Normalized name: Glutamic Acid
DrugBank: Glutamic acid (DB00142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamic acid hydrochloride (two 680-mg doses given 10 minutes apart) after ranitidine 300 mg (administered 1-2 hours prior)
Study: 1686581
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg (as hydrochloride salt)
Study: 6383993
Drug: Three-phase preparation
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-phase preparation containing levonorgestrel
Study: 6383993
Drug: Monophasic combination
Normalized name: Monobasic Potassium Phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monophasic combination preparations (levonorgestrel and desogestrel)
Study: 27955688
Drug: Pethidine intramuscular
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine intramuscular injection
Study: 24773166
Drug: Ondansetron 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.5 mg/d
Study: 22932119
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg lixivaptan once daily, titrated to 25-100 mg once daily depending on serum sodium concentration
Study: 20178636
Drug: Electroconvulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive therapy (ECT), 3 sessions per week for up to 6 weeks, total up to 18 sessions.
Study: 20178636
Drug: Algorithm-based pharmacological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm-based pharmacological treatment as usual.
Study: 17632760
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Impact for 7 days postoperatively, no preoperative treatment)
Study: 10606838
Drug: Caffeine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (mean dose: 550 mg day‐1, range: 400‐1000 mg day‐1)
Study: 7902024
Drug: Twice‐daily levocabastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice‐daily levocabastine
Study: 7902024
Drug: Twice‐daily oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice‐daily oral terfenadine
Study: 3895384
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg twice daily for 4 weeks
Study: 26898720
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplements (LNS-PL)
Study: 26898720
Drug: Iron and
Normalized name: beef,iron and wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron and folic acid tablets (IFA)
Study: 19414665
Drug: modified FOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified FOLFOX6 plus bevacizumab (5 mg/kg every 2 weeks x 26)
Study: 17707751
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard treatment with aspirin and clopidogrel)
Study: 15031791
Drug: Mucosal delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucosal delivery of canarypox virus vaccine (vCP 205)
Study: 15031791
Drug: Systemic delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic delivery of canarypox virus vaccine (vCP 205)
Study: 15031791
Drug: Systemic delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic delivery of rabies vaccine (subunit rabies vaccine)
Study: 11803987
Drug: 10% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbamide peroxide gel in a stock tray with anticavity whitening dentifrice and after‐bleaching whitening mouthrinse
Study: 7826493
Drug: GM1 100
Normalized name: Ganglioside GM1
DrugBank: Ganglioside GM1 (DB16948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM1 100 mg
Study: 31190497
Drug: Intradermal needling
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal needling combined with rehabilitation intervention